Aimmune Therapeutics Inc. (AIMT)

22.43
NASDAQ : Health Technology
Prev Close 21.79
Day Low/High 21.81 / 22.47
52 Wk Low/High 16.95 / 36.12
Avg Volume 516.30K
Exchange NASDAQ
Shares Outstanding 62.67M
Market Cap 1.37B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Aimmune Therapeutics Announces Appointment Of Dr. Brett Haumann To Board Of Directors

Aimmune Therapeutics Announces Appointment Of Dr. Brett Haumann To Board Of Directors

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.

Aimmune Therapeutics To Participate In Upcoming Investor Conferences

Aimmune Therapeutics To Participate In Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences: Stifel 2018...

Aimmune Therapeutics Announces Initiation Of Phase 2 Study With Regeneron And Sanofi Of AR101 With Adjunctive Dupilumab In Peanut-Allergic Patients

Aimmune Therapeutics Announces Initiation Of Phase 2 Study With Regeneron And Sanofi Of AR101 With Adjunctive Dupilumab In Peanut-Allergic Patients

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab...

My Options Strategy for These 2 Biotech Stocks

My Options Strategy for These 2 Biotech Stocks

It's weeks like this that I'm glad I have some 'dry powder' to deploy.

First Week Of AIMT November 16th Options Trading

First Week Of AIMT November 16th Options Trading

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Present At The Cantor Global Healthcare Conference On Wednesday, October 3

Aimmune Therapeutics To Present At The Cantor Global Healthcare Conference On Wednesday, October 3

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.

First Week Of AIMT October 19th Options Trading

First Week Of AIMT October 19th Options Trading

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Present At Three Investor Conferences In September

Aimmune Therapeutics To Present At Three Investor Conferences In September

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will present at three investor conferences in September: Wells Fargo...

Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018.

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present At The Wedbush PacGrow Healthcare Conference On Wednesday, August 15th

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present At The Wedbush PacGrow Healthcare Conference On Wednesday, August 15th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Let's check out the charts and indicators.

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

Jim Cramer explains why the fulcrum for the financial markets is growth -- not tariffs, or the Fed, or interest rates.

Aimmune Therapeutics Appoints Dr. Jayson Dallas As CEO

Aimmune Therapeutics Appoints Dr. Jayson Dallas As CEO

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Jayson Dallas, M.

Aimmune Therapeutics Announces Data On Terminology Used With Oral Immunotherapy Were Presented At EAACI 2018

Aimmune Therapeutics Announces Data On Terminology Used With Oral Immunotherapy Were Presented At EAACI 2018

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that data on terminology used with oral immunotherapy were presented at the European Academy of...

Aimmune Therapeutics Announces New Clinical Data On AR101 For Peanut Allergy At The 2018 EAACI Congress

Aimmune Therapeutics Announces New Clinical Data On AR101 For Peanut Allergy At The 2018 EAACI Congress

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, reported additional results from its pivotal Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy...

First Week Of AIMT July 20th Options Trading

Investors in Aimmune Therapeutics Inc saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Present Data On Peanut Allergy At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2018

Aimmune Therapeutics To Present Data On Peanut Allergy At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2018

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy at the European Academy of Allergy and Clinical...

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

Aimmune Therapeutics To Participate In Four Upcoming Investor Conferences In May And June

Aimmune Therapeutics To Participate In Four Upcoming Investor Conferences In May And June

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences...

Aimmune Therapeutics Announces First Quarter 2018 Financial Results

Aimmune Therapeutics Announces First Quarter 2018 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018.

Nike, Zebra Technologies, Blackstone: 'Mad Money' Lightning Round

Nike, Zebra Technologies, Blackstone: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Nike, Zebra Technologies, Blackstone, Ingersoll-Rand, Thermo Fisher Scientific and more.

Trade Barriers and Interest Rates: Cramer's 'Mad Money' Recap (Monday 4/23/18)

Trade Barriers and Interest Rates: Cramer's 'Mad Money' Recap (Monday 4/23/18)

Jim Cramer considers which is worse for stocks: the 10-year Treasury breaching 3% or the tariff battles with China.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

2 Biotech Stocks to Consider

2 Biotech Stocks to Consider

Many stocks are already at support levels and are offering opportunities to start some positions.

First Week of AIMT May 18th Options Trading

First Week of AIMT May 18th Options Trading

Investors in Aimmune Therapeutics Inc saw new options become available this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2017.

Aimmune Therapeutics To Participate In Four Investor Conferences In March

Aimmune Therapeutics To Participate In Four Investor Conferences In March

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in...

Aimmune Therapeutics Presents Results From The Positive, Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy At AAAAI-WAO

Aimmune Therapeutics Presents Results From The Positive, Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy At AAAAI-WAO

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that the results of its pivotal Phase 3 PALISADE trial of AR101 for the...

Aimmune Therapeutics Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Aimmune Therapeutics Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten...